Pat Killingsworth Pat Killingsworth

Kyprolis proving to be a surprisingly effective combination drug

Yesterday am I promised another post later in the day.  Sorry, but after I got home I fell asleep on the couch!   As promised, here are more of my notes and thoughts about myeloma related research from ASH.  In no particular order:

At the International Journalists’ press event Sunday night, Dr. Orlowski, noted that doubling the standard Kyprolis dose looks like it may significantly improve single agent results of 25%.

Speaking of Kyprolis (carfilzomib), it was also revealed that Car/Pom/Dex achieves 50% response rate in heavily pre-treated, refractory patients.  A clinical benefit totaling 67%  Longer response times, too!

And ARRY-520 plus Kyprolis was able to exceed the 50% response rate in relapsed patients in another small study.  Myeloma docs are obviously having fun experimenting with the first new FDA approved myeloma drug in over six years.  When combined with Dr. Berenson’s preliminary results showing how well Kyprolis works in a variety of combinations after patients become resistant to Velcade, it sounds to me like there may be more to Kyprolis than we originally thought.  And that would be very good news!

Feel good and keep smiling!  Pat